Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Allergy and Asthma Reports
Published in: Current Allergy and Asthma Reports 1/2012

01-02-2012 | Basic and Applied Science (M Frieri, Section Editor)

Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Role of Proinflammatory Cytokines and Therapeutic Approaches

Author: Marianne Frieri

Published in: Current Allergy and Asthma Reports | Issue 1/2012

Login to get access

Abstract

In systemic lupus erythematosus (SLE) patients, the role of inflammatory mediators is relevant to the pathogenesis of accelerated atherosclerosis. CD40 ligand is increased on circulating lymphocytes, correlates with double-stranded DNA, and has an important role in predicting risk of cardiovascular disease. Vascular endothelial growth factor (VEGF) is a tightly regulated angiogenic cytokine in the kidney, and plasma levels have been associated with disease activity. It has been correlated with lupus nephritis, associated with higher mean carotid intima media thickness, and can be a novel cardiovascular risk factor in premature coronary atherosclerosis. VEGF has been demonstrated in cultured human aortic endothelial cells in the presence of simvastatin and in kidney biopsies in lupus nephritis. SLE patients have been shown to manifest disturbances in gene expression involved in lipid transport and atheroma promotion. This paper provides evidence of the immune system in accelerated atherosclerosis in SLE, the role of selected proinflammatory cytokines, and therapeutic approaches.
Literature
1.
McMahon M, Hahn BH. Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr Opin Immunol. 2007;19(6):633–9.PubMedCrossRef
2.
• Fu HJ, Yuan M, Ren LF, Guo WY. The clinical research of serum soluble CD40L and high sensitive C-reactive protein in patients with acute coronary syndrome. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2011;27(2):180–1. This was an important study reviewing CD40L and inflammation related to ACS.
3.
Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006;26(5):987–94.PubMedCrossRef
4.
Steele R, Frieri M. Heat shock protein and sCD40 L stimulation of human keratinocytes. A model for cytokine profiling for cutaneous lupus. J Allergy Clin Immunol. 2008;121:P871.
5.
Yedowitz JC, Frieri M. Cytokine and growth factor production from chlamydia pneumoniae HSP 60 stimulated human aortic endothelial cells in the presence of simvastatin. Ann Allergy Asthma Immunol. 2009;102:P113.
6.
Seghal R, Jabber A, Anand A, Capetandes A, Frieri M. Monitoring CD 40 ligand in patients with SLE. J Allergy Clin Immunol. 2009;123:S16.CrossRef
7.
•• Frieri M. TLR and VEGF in human kidneys from lupus nephritis patients. J Nephrology. 2011, In review. This was a novel basic science study on the role of TLRs and VEGF in human kidneys from LN patients.
8.
Shirali AC, Goldstein DR. Tracking the toll of kidney disease. J Am Soc Nephrol. 2008;19(8):1444–50.PubMedCrossRef
9.
Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515–81.PubMedCrossRef
10.
Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 2009;78(6):539–52.PubMedCrossRef
11.
12.
Borba EF, Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol. 2001;28:780–5.PubMed
13.
•• Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol. 2011; 127:303–12. This is a very important, up-to-date, detailed article on novel therapies for SLE. PubMedCrossRef
14.
Dunn SE, Youssef S, Goldstein MJ, Prod’homme T, Weber MS, Zamvil SS, et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med. 2006;203:401–12.PubMedCrossRef
15.
Lopez-Pedrera C. Global effects of the HMG-CoA reductase inhibitor fluvastatin on the procoagulant and proinflammatory features of monocytes from APS patients. Ann Rheum Dis. 2009;68 suppl 3:245.
16.
Ferreira GA, Navarro TP, Telles RW, Andrade LE, Sato EI. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology (Oxford). 2007;46:1560–5.CrossRef
17.
Kotyla PJ, Sliwinska-Kotyla B, Kucharz EJ. Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMGCoA reductase inhibitor simvastatin. J Rheumatol. 2006;33:2361–3.PubMed
18.
Bianchi S, Bigazzi R, Caiazza A, Campese VM. A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003;41:565–70.PubMedCrossRef
19.
Kurien BT, Scofield RH. Autoimmunity and oxidatively modified autoantigens. Autoimmun Rev. 2008;7(7):567–73.PubMedCrossRef
20.
Fischer K, Brzosko M. Diagnosis of early atherosclerotic lesions, and selected atherosclerotic risk factors, in patients with systemic lupus erythematosus. Pol Arch Med Wewn. 2009;119(11):736–42.PubMed
21.
• Torres A, Askari AD, Malemud CJ. Cardiovascular disease complications in systemic lupus erythematosus. Biomark Med. 2009; 3(3):239–52. This is a useful article on various cardiovascular issues related to SLE. CrossRef
22.
•• Reiss AB. Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus. Curr Rheumatol Rep. 2009; 11(4):255–60. This is an extensive review on the role of inflammation and cholesterol related to SLE. PubMedCrossRef
23.
Reiss AB. Presented at the American Federation of Medical Research Workshop-, April 27, 2011.
24.
Frieri M. Cardiovascular risk in autoimmune rheumatic disorder. Presented at the American Federation of Medical Research Workshop, April 27, 2011.
25.
Reiss AB, et al. Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis. Exp Biol Med. 2009;234(3):354–60.CrossRef
26.
Reiss AB, Patel CA, Rahman M, Chan ES, Hasneen K, Montesinos C, Trahman JD, Cronstein BN. Interferon-gamma impedes reverse cholesterol transport and promotes foam cell transformation in THP-1 human monocytes/macrophages. Med Sci Monit. 2004;1-:BR420–BR425.
27.
Bingham TC, Fisher EA, Parathath S, Reiss AB, Chan ES, Cronstein BN. A2A adenosine receptor stimulation decreases foam cell formation by enhancing ABCA1-dependent cholesterol efflux. J Leukoc Biol. 2010;87(4):683–90.PubMedCrossRef
28.
•• Lopez-Pedrera C, Angeles Aguirre M, Barbarroja N. Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. J Biomed Biotechnol. Volume. 2010, Article ID 607084, 13. This is an excellent article on the role of cytokines and treatments related to accelerated atherosclerosis in SLE.
Metadata
Title
Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Role of Proinflammatory Cytokines and Therapeutic Approaches
Author
Marianne Frieri
Publication date
01-02-2012
Publisher
Current Science Inc.
Published in
Current Allergy and Asthma Reports / Issue 1/2012
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-011-0236-1

Other articles of this Issue 1/2012

Current Allergy and Asthma Reports 1/2012 Go to the issue

Basic and Applied Science (M Frieri, Section Editor)

Eosinophilic Disorders in Various Diseases

Anaphylaxis and Drug Allergy (P Lieberman and S Spector, Section Editors)

Vaccines and Immunomodulatory Therapies for Food Allergy

Anaphylaxis and Drug Allergy (P Lieberman and S Spector, Section Editors)

The Likelihood of Remission of Food Allergy in Children: When Is the Optimal Time for Challenge?

Basic and Applied Science (M Frieri, Section Editor)

Modulating Toll-like Receptor 7 and 9 Responses as Therapy for Allergy and Autoimmunity

Anaphylaxis and Drug Allergy (P Lieberman and S Spector, Section Editors)

Mediators Released During Human Anaphylaxis

Anaphylaxis and Drug Allergy (P Lieberman and S Spector, Section Editors)

Management of Multiple Drug Allergies in Children